Stock ONCOMED PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Oncomed Pharmaceuticals Inc

Equities

US68234X1028

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Celgene Corporation Announces Update on Etigilimab Partnership
CI
OncoMed Pharmaceuticals, Inc. Announces Executive Resignations in Connection with the Merger Agreement
CI
OncoMed Pharmaceuticals, Inc.(NasdaqGM:OMED) dropped from NASDAQ Composite Index
CI
Mereo BioPharma Group plc completed the acquisition of OncoMed Pharmaceuticals, Inc. from Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., MSI BVF SPV, LLC and Biotechnology Value Trading Fund OS LP managed by BVF Partners LP and others.
CI
OncoMed Pharmaceuticals, Inc.(NasdaqGS:OMED) dropped from S&P TMI Index
CI
OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights
GL
OncoMed Pharmaceuticals, Inc. Declares Special Dividend of Contingent Value Rights, Payable on April 5, 2019
CI
OncoMed Announces Fourth Quarter and Full Year 2018 Financial Results
GL
OncoMed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2018
CI
Oncomed Pharmaceuticals, Inc. Announces Executive Changes
CI
Transcript : Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc. - M&A Call
Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals
GL
Mereo BioPharma Group plc agreed to acquire OncoMed Pharmaceuticals, Inc. for $57.4 million.
CI
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody
GL
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody
CI
Oncomed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Provides Earnings Guidance for the Year 2018
CI
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
GL
OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer
GL
Celgene Notifies OncoMed Pharmaceuticals, Inc. of Its Decision Not to Exercise Option to License Rosmantuzumab and Subsequently Terminated the Companies’ Collaboration Agreement with Respect to Rosmantuzumab, Effective February 12, 2019
CI
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Oncomed Pharmaceuticals Inc